Background Eculizumab is a monoclonal antibody for the treatment of atypical hemolytic
uremic syndrome (aHUS). Kidney damage, a common condition in patients with aHUS, may …

Objective To describe how maintenance eculizumab sustains improved renal function in
severe atypical hemolytic uremic syndrome (aHUS). Case report A previously described 50 …

Atypical hemolytic uremic syndrome (aHUS) is a life-threatening disorder for which prompt
diagnosis and eculizumab treatment is indicated. The time for relapse and patients at risk for …

Background Atypical hemolytic uremic syndrome (aHUS) is characterized by platelet
consumption, hemolysis, and renal injury. Eculizumab, a humanized antibody that blocks …

Background The introduction of eculizumab has significantly improved the outcome of
patients with atypical haemolytic uraemic syndrome (aHUS). Because of the risk of relapse …

Background Eculizumab is a lifesaving yet expensive drug for atypical haemolytic uraemic
syndrome (aHUS). Current guidelines advise a fixed-dosing schedule, which can be …

Background Eculizumab is approved for atypical hemolytic uremic syndrome (aHUS).
Guidelines discuss the importance of prompt treatment. We report a post hoc analysis …

Recent studies indicate that eculizumab is often given in excess to atypical hemolytic uremic
syndrome (aHUS) patients. Individualization of treatment is thus highly requested; however …

Introduction The introduction of eculizumab has improved the outcome in patients with
atypical hemolytic uremic syndrome (aHUS). The optimal treatment strategy is debated …

Background Atypical hemolytic uremic syndrome (aHUS) is a devastating form of renal
thrombotic microangiopathy. Despite plasma exchange, the standard treatment of aHUS for …